Q2 FY2026 EarningsQ2 FY2026 results missed consensus on both top and bottom lines. Total revenue was $4.05M vs. the $7.85M expected, largely due to a significant decline in licensing and royalty revenue. Net loss widened to $55.4M, resulting in a GAAP EPS of -$0.18, trailing the consensus estimate of -$0.16. Despite the financial miss, the company secured new T-cell engager (TCE) collaborations with Jazz Pharmaceuticals and Vertex, adding over $100M in non-dilutive upfront cash to its liquidity profile.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Abcellera Biologics(ABCL) the Revenue is 4.05 M (-76.29%), Miss estimate;the EBIT is -62.78 M (-26.6%), Miss estimate;the EPS is -0.18 (-50%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B76.29%
0.01B54.06%
-0.00B22.23%
EBITMiss expectations
-0.06B26.60%
-0.06B22.40%
-0.00B4.20%
EPSMiss expectations
-0.1850.00%
-0.163336.11%
-0.016713.89%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf